Spark Therapeutics, Inc. (ONCE)
(Delayed Data from NSDQ)
$108.03 USD
+1.03 (0.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $108.08 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$108.03 USD
+1.03 (0.96%)
Updated May 3, 2019 04:00 PM ET
After-Market: $108.08 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC
by Zacks Equity Research
Roche (RHHBY) obtains approval for the label expansion of Tecentriq in Europe. The company also submits its sNDA for leukemia drug, Venclexta.
Biogen to Acquire Gene-Therapy Company Nightstar for $800M
by Zacks Equity Research
Biogen (BIIB) to acquire gene-therapy company, Nightstar Therapeutics to accelerate entry into ophthalmology space.
Pharma Stock Roundup: Roche to Buy ONCE, Lawmakers Grill CEOs Over High Drug Prices
by Zacks Equity Research
Roche (RHHBY) to buy Spark Therapeutics for $4.8 billion. Executives of big pharma companies face senators' questions over high drug prices.
Biotech Stock Roundup: ONCE, CMTA Soar on Merger News, Other Pipeline Updates
by Zacks Equity Research
Key highlights of the past week are merger agreements, and regulatory and pipeline developments.
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
Company News For Feb 26, 2019
by Zacks Equity Research
Companies In The News Are: DHR,GE,ONCE,CMTA,CRI
5 Gene Therapy Stocks to Enrich Your Portfolio
by Tirthankar Chakraborty
Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.
Roche (RHHBY) to Acquire Spark Therapeutics for $4.8 Billion
by Zacks Equity Research
Roche (RHHBY) to acquire Philadelphia-based gene therapy company, Spark Therapeutics, Inc. (ONCE) at a price of $114.50 per share in an all-cash transaction.
Spark Therapeutics (ONCE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y
by Zacks Equity Research
Novartis (NVS) misses estimates in Q4 as generic unit continues to face challenging business conditions. The outlook for 2019 didn't impress investors either.
Novartis (NVS) Benefits From New Drugs & Key Acquisitions
by Zacks Equity Research
Novartis (NVS) gets a boost from strong performance of new drugs. Strategic acquisitions to foray into promising areas has also boosted investor sentiment.
Novartis (NVS) Offers to Buy French Gene Therapy Manufacturer
by Zacks Equity Research
Novartis (NVS) looks to buy French company, CellforCure to expand manufacturing capacity for innovative cell and gene therapies.
Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News
by Zacks Equity Research
Pipeline and regulatory updates are the key highlights in the biotech sector this week.
Spark Therapeutics' Luxturna Gets EU Approval for Vision Loss
by Zacks Equity Research
Spark Therapeutics (ONCE) announces approval in Europe for its gene therapy, Luxturna, for treating inherited retinal dystrophy with RPE65 mutation. Novartis will develop and distribute it in Europe.
uniQure Up on Positive Data From Mid-Stage Hemophilia Study
by Zacks Equity Research
uniQure's (QURE) gene therapy candidate, AMT-061, demonstrates significant improvement in hemophilia B patients in a mid-stage study. Investors' sentiment improves.
Spark Therapeutics (ONCE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Spark Therapeutics (ONCE) delivered earnings and revenue surprises of -21.15% and -58.95%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Spark Therapeutics (ONCE) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Novartis (NVS) Q3 Earnings In Line, Revenues Beat Estimates
by Zacks Equity Research
Novartis (NVS) beats sales estimates in Q3, driven by Cosentyx and Entresto, while earnings came in line. The company plans to acquire Endocyte to broaden its oncology pipeline.
Novartis Presents Positive Data on Sickle Cell Disease Drug
by Zacks Equity Research
Novartis (NVS) announces positive results from a post hoc analysis of the phase II study, SUSTAIN, on pipeline candidate, crizanlizumab, being published in the American Journal of Hematology.
Novartis Gets Positive CHMP Opinion for Drugs, Biosimilar
by Zacks Equity Research
Novartis (NVS) gets positive CHMP opinion for a label expansion of Gilenya, gene therapy, and a biosimilar of Neulasta.
Novartis to Sell Sandoz's Dermatology Business to Aurobindo
by Zacks Equity Research
Novartis (NVS) looks to sell Sandoz's dermatology business in the United States and generic U.S. oral solids portfolio, to Aurobindo Pharma USA Inc., for $0.9 billion.
Novartis' CAR-T Therapy Kymriah Gets Approval in Europe
by Zacks Equity Research
Novartis (NVS) gets EC approval for CAR-T therapy, Kymriah, for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia.
Biotech Stock Roundup: Regeneron Shines, BLUE Surges, ONCE Plunges
by Zacks Equity Research
The last leg of Q2 earnings in the biotech sector saw Regeneron firing all cylinders. The company also collaborated with bluebird bio, which impressed investors.
Spark Therapeutics (ONCE) Q2 Earnings Beat Estimates
by Zacks Equity Research
Spark Therapeutics (ONCE) delivered earnings and revenue surprises of 581.40% and -14.44%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?